Cartesian Therapeutics Inc. Total Liabilities
Cartesian Therapeutics Inc. total liabilities. Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has total liabilities worth $436.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cartesian Therapeutics Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cartesian Therapeutics Inc. (2014–2025)
Total liabilities of Cartesian Therapeutics Inc. from 2014 to 2025. This chart illustrates how Cartesian Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Cartesian Therapeutics Inc. (RNAC) investment intensity to see how much of total assets are deployed in long-term investments.
Cartesian Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
Israel | ILA1.25 Billion |
|
New World Resources Ltd
AU:NWC
|
Australia | AU$1.75 Million |
|
W-SCOPE CHUNGJU PLANT LTD (PROPOSE
KQ:393890
|
Korea | ₩1.05 Trillion |
|
Chain Bridge Bancorp, Inc.
NYSE:CBNA
|
USA | $2.01 Billion |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
USA | $12.99 Million |
|
Plano & Plano Desenvolvimento Imobiliário S.A
SA:PLPL3
|
Brazil | R$2.84 Billion |
|
Kolon Corp
KO:002020
|
Korea | ₩4.72 Trillion |
|
Long Table Growth Corp. Class A Ordinary Shares
NASDAQ:LTGR
|
USA | $10.51 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Cartesian Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Cartesian Therapeutics Inc..
Liquidity & Leverage Metrics
Cartesian Therapeutics Inc. Total Liabilities Ratios Explained
Cartesian Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cartesian Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual total liabilities of Cartesian Therapeutics Inc. from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $422.65 Million | -4.34% |
| 2024-12-31 | $441.82 Million | -40.71% |
| 2023-12-31 | $745.23 Million | +934.21% |
| 2022-12-31 | $72.06 Million | -47.54% |
| 2021-12-31 | $137.36 Million | -25.12% |
| 2020-12-31 | $183.44 Million | +101.20% |
| 2019-12-31 | $91.17 Million | +82.71% |
| 2018-12-31 | $49.90 Million | +1.25% |
| 2017-12-31 | $49.29 Million | +43.51% |
| 2016-12-31 | $34.34 Million | -78.44% |
| 2015-12-31 | $159.32 Million | +44.86% |
| 2014-12-31 | $109.98 Million | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more